MedPath
Found 47 clinical trials|View Analysis
Sort by:

Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors

Phase 1
Not yet recruiting
Conditions
Solid Tumor Cancer
Interventions
Drug: Liposomal irinotecan in combination with vincristine and temozolomide
First Posted Date
2024-11-28
Last Posted Date
2024-11-28
Lead Sponsor
Yizhuo Zhang
Target Recruit Count
40
Registration Number
NCT06710821

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

Not Applicable
Recruiting
Conditions
Treatment
Neoantigen
Vaccine
Solid Tumor Cancer
Interventions
First Posted Date
2024-11-12
Last Posted Date
2024-11-19
Lead Sponsor
Fudan University
Target Recruit Count
9
Registration Number
NCT06682117
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

Phase 1
Withdrawn
Conditions
Testicular Cancer
CLDN6-positive Solid Tumor
Ovarian Cancer
Endometrial Cancer
Metastatic or Locally Advanced Solid Tumor Cancer
Non-small Cell Lung Cancer
Interventions
Drug: ASP1893
First Posted Date
2024-11-08
Last Posted Date
2024-12-11
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
197
Registration Number
NCT06681870

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not Applicable
Not yet recruiting
Conditions
Solid Tumor Cancer
Chemotherapy Induced Neutropenia
G-CSF
Interventions
Drug: Efbemalenograstim alfa Injection
Drug: Carboplatin plus Paclitaxel
Drug: carboplatin/cisplatin-etoposide
Drug: TP regimen
Drug: Cisplatin/pemetrexed or Carboplatin/pemetrexed
First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
Shandong Cancer Hospital and Institute
Target Recruit Count
200
Registration Number
NCT06649448
Locations
🇨🇳

Shandong Cancer Hospital and Institute, Jinan, Shandong, China

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Solid Cancers
Solid Tumor Cancer
Solid Tumor Malignancy
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Metastatic Solid Tumor
Locally Advanced Solid Tumor
Urothelial Cancer of Renal Pelvis
Interventions
Drug: XL495
Drug: ADC cytotoxic agents
First Posted Date
2024-10-08
Last Posted Date
2024-12-20
Lead Sponsor
Exelixis
Target Recruit Count
124
Registration Number
NCT06630247
Locations
🇺🇸

Exelixis Clinical Site #3, Nashville, Tennessee, United States

🇺🇸

Exelixis Clinical SIte #2, Huntersville, North Carolina, United States

🇺🇸

Exelixis Clinical Site #1, Austin, Texas, United States

A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

Recruiting
Conditions
Diffuse Large B Cell Lymphoma
Solid Tumor Cancer
First Posted Date
2024-10-03
Last Posted Date
2024-10-03
Lead Sponsor
OWKIN
Target Recruit Count
7000
Registration Number
NCT06625203
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇫🇷

Gustave Roussy, Paris, France

🇩🇪

Charité - Universitätsmedizin Berlin, Berlin, Germany

and more 2 locations

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Phase 2
Recruiting
Conditions
Solid Tumor Cancer
Medulloblastoma
High Risk Neuroblastoma
High Grade Gliomas
Meningioma
Paraganglioma
Pheochromocytoma
Neuroendocrine Tumours (NET)
Adrenal Tumours
Interventions
First Posted Date
2024-09-23
Last Posted Date
2024-10-21
Lead Sponsor
Fundación de investigación HM
Target Recruit Count
25
Registration Number
NCT06607692
Locations
🇪🇸

HM Monteprincipe, Boadilla del Monte, Madrid, Spain

A Study of Exercise Therapy in People With Solid Tumor Cancer

Phase 1
Recruiting
Conditions
Solid Tumor Cancer
Interventions
Other: Exercise therapy
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
150
Registration Number
NCT06597786
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

Phase 2
Recruiting
Conditions
Advanced Cancer
Stage IV Melanoma
Endocrine Cancer
Stage IV Solid Tumor Cancer
Stage IV Sarcoma of Bone
Stage IV Lymphoma
Interventions
First Posted Date
2024-05-16
Last Posted Date
2024-07-16
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
15
Registration Number
NCT06416085
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Expanded Access to ABBV-CLS-484

Conditions
Advanced Solid Tumor Cancer
First Posted Date
2024-01-03
Last Posted Date
2024-01-03
Lead Sponsor
Calico Life Sciences LLC
Registration Number
NCT06188975
© Copyright 2025. All Rights Reserved by MedPath